Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.
Janssen’s investigational hepatitis C drug simeprevir received a unanimous recommendation for approval from a U.S. FDA panel.
Apparently guidelines have changed; 12 weeks post treatment is when you get the all-clear now.
The good news is I’ve got a bit of a rash. Rashes are a characteristic symptom of protease inhibitors.
Abbott has announced Phase III trials of three direct acting agents, ABT-450/r, ABT-267, ABT-333, which together have shown high cure rates in...
Antiviral therapies faldaprevir and BI 207127 are safe and effective among people with hepatitis C virus, including those with advanced liver...
Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...
Boehringer Ingelheim, a Germany-based company known for its successful development of two HIV drugs and ongoing study of two hepatitis C medic...
Many people living with hepatitis C virus (HCV) can’t wait until all-oral, potentially less toxic regimens become available.
A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...
Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured
Two new Phase III clinical trials of the hepatitis C protease inhibitor TMC435, being developed by Medivir and Janssen Pharmaceuticals, have b...
An international Hep C activist group is calling on government regulators and pharmaceutical companies developing therapies for HCV...
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...
The odds of curing hep C are now better than ever.
The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.